DGAP-News: ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015

DGAP-News: Alacris Theranostics GmbH / Key word(s): Miscellaneous/Miscellaneous ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015 28.04.2015 / 13:30 --------------------------------------------------------------------- Press Release ______________________________________________________________ ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015 ______________________________________________________________ Berlin, 28th April 2015 - Alacris Theranostics GmbH announced today that they have been awarded the highly renowned German Innovation Award 2015. Alacris Theranostics received the award in the category Medium-Sized Enterprises for ModCellTM, an innovative system biology-based modelling approach for personalised diagnostics, therapy and drug stratification with an initial focus on cancer. ModCellTM can predict potential effects and side effects of treatments on the basis of a detailed molecular analysis of the patient's tumor to support physicians in their decision making for an optimized therapy for each individual patient (currently in a clinical trial). In addition, ModCellTM can be used in both, biomarker identification and for the development and repositioning of drugs. By simulating drug activity in "virtual clinical trials", ModCellTM allows for a faster, more efficient drug development and approval process. The unique feature of ModCellTM is the use of a systems biology model in the field of personalised medicine which is significantly different from statistical, correlative approaches, in most cases based only on single or multiple biomarkers. The analysis of individual biomarkers allows only examination of a partial aspect of the disease. ModCellTM however, generates a computer model of a "virtual patient" on the basis of analysing the totality of the biological data and therefore helps to identify individualised, promising treatment strategies for cancer patients. "We are delighted that the jury of the German Innovation Award has honoured our innovative ModCellTM modelling approach," commented Bodo Lange, PhD, CEO of Alacris Theranostics GmbH. "The award is an important recognition of our approach and our work. This prize further encourages us to continuously develop and improve ModCellTM for achieving the best possible treatment for patients in the fight against cancer." Alacris has established its own state-of-the-art Next Generation Sequencing Laboratory in Berlin with the appropriate sequencing and data analysis capabilities in order to generate data for the modelling of patients and tumours. With the development and commercialisation of this innovation in personalised healthcare, Alacris also attracts highly qualified international young scientists to the Berlin area. Berlin plays an important role as an attractive location for researchers, companies, founders and consequently investors. About German Innovation Award In 2010, Accenture, EnBW, Evonik and Wirtschaftswoche jointly formed the initiative "The German Innovation Award" to reward German companies with outstanding, pioneering innovations that have the potential to change business and markets. The prize is awarded in three categories to large companies, medium sized enterprises and start-ups. In addition to product innovations and innovative business models, the jury also considered processes, services and outstanding organisational and marketing innovations. About Alacris Theranostics GmbH Berlin-based Alacris Theranostics (www.alacris.de), a spin-off from the Max Planck Institute for Molecular Genetics, develops new approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. The Company is applying the systems biology approach ModCellTM to provide a "Virtual Patient" model based on genome and transcriptome information obtained by next generation sequencing, mutation and drug databases as well as complex pathway information. This "Virtual Patient" model can predict the effects of drug treatment and optimised combinatory treatments to provide the means for truly personalised medicine approaches. In addition, Alacris' "Virtual Clinical Trials" system enables the in silico analysis of drugs, thus identifying stratified patient groups with particular genetic and molecular profiles that could be targeted by a drug to allow more efficient drug development and approval. # # # Contact: Alacris Theranostics GmbH Dr Bodo Lange, CEO Fabeckstrasse 60-62 D-14195 Berlin Germany Phone: + 49 30 8431 22 510 Email: info@alacris.de www.alacris.de MC Services AG Anne Hennecke, Managing Partner Tel.: +49 211 529 252 22 Email: anne.hennecke@mc-services.eu --------------------------------------------------------------------- 28.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 349739 28.04.2015

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Neurotrope, Inc. Achieves New Milestone with Stock Surge

Updated Category News Views 147

Neurotrope, Inc. Reaches New Stock Milestone Neurotrope, Inc. (NASDAQ: NTRP) has recently achieved a significant milestone in the stock market, soaring to a 52-week high with its price reaching $7.00. This impressive climb indicates a remarkable 124.95% increase over the past year, showcasing strong investor interest and confidence in the company's future prospects. The...

Continue Reading
Lil Nas X's Legal Challenges and Public Struggles Unfold

Updated Category News Views 284

Lil Nas X Pleads Not Guilty to Serious Charges Grammy-winning musician Lil Nas X has recently made headlines for pleading not guilty to multiple felony charges stemming from an incident involving police officers. This situation arose when he was found walking unclothed on the streets of Los Angeles. Understanding the Legal Battle Ahead The rapper, known legally as Montero...

Continue Reading
Exyte's Strategic Acquisition of TTP Group Enhanced Operations

Updated Category News Views 51

Exyte Acquires TTP Group to Strengthen Engineering Expertise Exyte, a leader in high-tech facility engineering, has officially completed the acquisition of TTP Group, enhancing its operations and expertise especially in the biopharma and life sciences sectors. This acquisition marks a significant milestone for Exyte as it melds TTP's capabilities with its own, aiming to...

Continue Reading
Unveiling Health Innovations: Zepp Health at CES 2024 Events

Updated Category News Views 372

Zepp Health Showcases Innovative Technologies at CES Zepp Health Corporation (NYSE: ZEPP), a leader in health technology and smart wearables, is excited to announce its participation in significant media events like Pepcom and ShowStoppers at CES. These occasions will showcase Zepp Health's latest advancements in smart wearables and health technologies, aimed at...

Continue Reading
Meridian Locks $186M Loan for NJ Condo Project

Updated Category News Views 163

New Jersey's Coastline Gets a $186 Million Facelift Here's a move that'll shake the Jersey Shore awake: Meridian Capital Group's just put their money where the sand is with a massive $186 million scoop for a new high-end condominium project in Asbury Park. You couldn't make up a better setting—a beachfront spot ripe for some high-end living. But let's not get too...

Continue Reading